Dataset Information

Preferences for Temporal Sequences of Real Outcomes Differ Across Domains but do not Vary by Age.

ABSTRACT:

Objectives

People's preferences for temporal sequences of events have implications for life-long health and well-being. Prior research suggests that other aspects of intertemporal choice vary by age, but evidence for age differences in sequence-preferences is limited and inconclusive. In response, the present research examined age differences in sequence-preferences for real outcomes administered in a controlled laboratory setting.

Methods

A pilot study examined sequence-preferences for aversive electrodermal shocks in 30 younger and 30 older adults. The main study examined sequence-preferences for electrodermal shocks, physical effort, and monetary gambles in an adult life-span sample (N = 120). It also examined emotional and physiological responses to sequences as well as underlying mechanisms including time perception and emotion-regulation.

Results

There were no significant age differences in sequence-preferences in either of the studies, and there were no age differences in responses to sequences in the main study. Instead, there was a domain effect with participants preferring decreasing sequences for shocks and mixed sequences for effort and money.

Discussion

After considering potential methodological limitations, theoretical contributions and implications for real-life decisions are discussed.

SUBMITTER: Lockenhoff CE

PROVIDER: S-EPMC6377032 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Preferences for Temporal Sequences of Real Outcomes Differ Across Domains but do not Vary by Age.

Löckenhoff Corinna E CE Rutt Joshua L JL Samanez-Larkin Gregory R GR O'Donoghue Ted T Reyna Valerie F VF

The journals of gerontology. Series B, Psychological sciences and social sciences 20190201 3

<h4>Objectives</h4>People's preferences for temporal sequences of events have implications for life-long health and well-being. Prior research suggests that other aspects of intertemporal choice vary by age, but evidence for age differences in sequence-preferences is limited and inconclusive. In response, the present research examined age differences in sequence-preferences for real outcomes administered in a controlled laboratory setting.<h4>Methods</h4>A pilot study examined sequence-preferenc ...[more]

PMID: 28977554

Similar Datasets

Project description:ObjectivesThe treatment landscape for metastatic renal cell carcinoma changed a lot in the last few years. This study aimed to assess the treatment sequences and outcomes for metastatic renal cell carcinoma in a real-world setting.Materials and methodsWe enrolled patients with metastatic renal cell carcinomawho received first-line systemic treatment with tyrosin kinase inhibitors monotherapy, ipilimumab plus nivolumab, or pembrolizumab plus axitinibbetween January2009 and May 2023 on the database of TriNetX network. Overall survival, time on treatment and time to next treatment were evaluated using Kaplan-Meiermethod.ResultsTotally, 4183 received tyrosine kinase inhibitor monotherapy, 1555 received ipilimumab plus nivolumab, and 559 received axitinib plus pembrolizumab. Median time on treatment was 2.5 months for the tyrosine kinase inhibitor monotherapy cohort, 5.4 months for the ipilimumab plus nivolumab cohort, and 8.3 months for the pembrolizumab plus axitinib cohort. Median time to next treatment was 16.6 months for both the tyrosine kinase inhibitor monotherapy and ipilimumab plus nivolumab cohorts, and 22.1 months for the pembrolizumab plus axitinib cohort. Median overall survival was 42.2 months for the tyrosine kinase inhibitor monotherapy cohort, 39.7monthsfor the ipilimumab plus nivolumab cohort, and not reached for the pembrolizumab plus axitinib cohort. In comparison with the tyrosine kinase inhibitor monotherapy cohort, patients in the pembrolizumab plus axitinib cohort showed survival benefit (log-rank p = 0.0168) in overall survival, but not the case in the ipilimumab plus nivolumab cohort.ConclusionThere was a trend toward using first-line immuno-oncology based therapy for patients with metastatic renal cell carcinoma in a real-world practice. Axitinib plus pembrolizumuab cohort had survival benefits over tyrosine kinase inhibitor and ipilimumab plus nivolumab cohorts, while patients in the ipilimumab plus nivolumab cohort had more distant metastases and comorbidities.

Dataset Information

Preferences for Temporal Sequences of Real Outcomes Differ Across Domains but do not Vary by Age.

Objectives

Methods

Results

Discussion

Publications

Preferences for Temporal Sequences of Real Outcomes Differ Across Domains but do not Vary by Age.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets